FMC and Corteva Partner to Expand Rimisoxafen Herbicide Access

What happened

FMC Corporation and Corteva announced a co-exclusive supply and license agreement that will expand access to FMC's rimisoxafen herbicide technology for corn and soybean growers in North and South America, adding a dual mode-of-action tool to combat resistant weeds. While the deal validates FMC's innovation pipeline, it does not address the company's pressing liquidity constraints; FMC reported negative operating cash flow of $663 million for the first nine months of 2025 and net debt of $3.14 billion. The agreement is structured as a supply and license deal, meaning FMC will likely receive upfront and milestone payments, but the revenue contribution will be phased over several seasons. This partnership provides a strategic endorsement from a well-capitalized peer (Corteva) but does not alter the near-term working capital dynamics that are the primary driver of FMC's equity value. The core investment thesis remains tied to FMC's ability to convert Latin American receivables into cash without further credit erosion, not to isolated product-level wins.

Implication

Investors should view this partnership as constructive for FMC's long-term product portfolio and likely to generate modest licensing revenue, but it does not resolve the company's balance sheet stress. The near-term equity performance will continue to hinge on working capital improvements and covenant compliance, not product announcements. Until FMC demonstrates sustainable positive operating cash flow and net debt reduction, the risk-reward is skewed to the downside, with attractive entry at $14 and a trim level at $22.

Thesis delta

This news slightly improves FMC's competitive position by demonstrating the value of its patented herbicide technology and securing a co-exclusive deal with a strong partner, which could lead to additional licensing opportunities. However, the deal does not alter the company's immediate cash flow crisis or the need for aggressive working capital management. The core thesis remains that FMC is a levered turnaround where equity returns depend on cash conversion, not pipeline milestones; thus the rating stays at WAIT.